Join
Live feed
·
PRReleasevia Quantisnow
VYNE Therapeutics Inc. logo

VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited

ByQuantisnow·Wall Street's wire, on your screen.
VYNE· VYNE Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VYNE (VYNE Therapeutics Inc.) and more on Quantisnow.